Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2021-04-09
- Target Recruit Count
- 36
- Registration Number
- NCT01045460
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT01039025
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 74
- Registration Number
- NCT01035463
- Locations
- 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 176
- Registration Number
- NCT01010217
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
- Conditions
- Recurrent Childhood Hodgkin LymphomaRefractory Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaPlasma Cell LeukemiaProgression of Multiple Myeloma or Plasma Cell LeukemiaRecurrent Adult Non-Hodgkin LymphomaRecurrent Childhood Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Childhood Hodgkin Lymphomat(14;16)
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CyclophosphamideDrug: CytarabineDrug: EtoposideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01008462
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00995059
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00992446
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
- Conditions
- Interventions
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 101
- Registration Number
- NCT00985959
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
- Conditions
- Germ Cell TumorRecurrent MedulloblastomaEmbryonal Tumor With Multilayered Rosettes, C19MC-AlteredMedulloblastomaMedulloepitheliomaRecurrent Malignant Germ Cell TumorRecurrent Primitive Neuroectodermal TumorPrimitive Neuroectodermal TumorCentral Nervous System Embryonal NeoplasmRecurrent Childhood Central Nervous System Embryonal Neoplasm
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00983398
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Infusion of Expanded Cord Blood T Cells
- Conditions
- Interventions
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00972101
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.